Evidence map›Paper›PMID 34673031›Full record

ArticleThe Journal of biological chemistry2021

Phosphorylation regulates arginine-rich RNA-binding protein solubility and oligomerization.

Sean R Kundinger, Eric B Dammer, Luming Yin, Cheyenne Hurst, Sarah Shapley, Lingyan Ping, Sohail Khoshnevis, Homa Ghalei, Duc M Duong, Nicholas T Seyfried

Open access · goldAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Non-Enzymatic MGO-Glycation of SRSF2 Drives RNA Mis-Splicing.Journal of the American Chemical Society · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Sean R KundingerDepartment of Biochemistry, Emory University, Atlanta, Georgia, USA.
Eric B DammerDepartment of Biochemistry, Emory University, Atlanta, Georgia, USA.
Luming YinDepartment of Biochemistry, Emory University, Atlanta, Georgia, USA.
Cheyenne HurstDepartment of Biochemistry, Emory University, Atlanta, Georgia, USA.
Sarah ShapleyDepartment of Biochemistry, Emory University, Atlanta, Georgia, USA.
Lingyan PingDepartment of Biochemistry, Emory University, Atlanta, Georgia, USA.
Sohail KhoshnevisDepartment of Biochemistry, Emory University, Atlanta, Georgia, USA.
Homa GhaleiDepartment of Biochemistry, Emory University, Atlanta, Georgia, USA.
Duc M DuongDepartment of Biochemistry, Emory University, Atlanta, Georgia, USA.
Nicholas T SeyfriedDepartment of Biochemistry, Emory University, Atlanta, Georgia, USA; Department of Neurology, Emory University School of Medicine, Atlanta, Georgia, USA. Electronic address: nseyfri@emory.edu.
Emory University · US

Funding

Supplement to AMP-AD Brain Proteomic Network Enhancement, Validation and Translation into CSF BiomarkersU01AG061357 · NIA · EMORY UNIVERSITY · PI LEVEY, ALLAN I, SEYFRIED, NICHOLAS THOMAS · 2018 to 2022
$9.1M
Discovery of Novel Proteomic Targets in Alzheimer's DiseaseU01AG046161 · NIA · EMORY UNIVERSITY · PI BENNETT, DAVID ALAN, GESCHWIND, DANIEL H · 2014 to 2018
$8.4M
Identifying therapeutic targets that confer synaptic resilience to Alzheimer's diseaseR01AG061800 · NIA · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Christopher A. Gaiteri, Jeremy H. Herskowitz · 2018 to 2026
$6.9M
Training Program in Biochemistry, Cell and Molecular BiologyT32GM008367 · NIGMS · EMORY UNIVERSITY · PI BOISE, LAWRENCE H., CORBETT, ANITA H. · 1990 to 2019
$5.6M
TRAINING IN TRANSLATIONAL RESEARCH IN NEUROLOGYT32NS007480 · NINDS · EMORY UNIVERSITY · PI LEVEY, ALLAN I · 2000 to 2020
$4.5M
Glycoproteomics and the Glycosylation Code of the Brain in Asymptomatic and Symptomatic Alzheimer’s DiseaseRF1AG062181 · NIA · BETH ISRAEL DEACONESS MEDICAL CENTER · PI CUMMINGS, RICHARD D, SEYFRIED, NICHOLAS THOMAS · 2018 to 2018
$4.1M
Tau-Spliceosome Interactions in Alzheimer's DiseaseR01AG053960 · NIA · BAYLOR COLLEGE OF MEDICINE · PI SEYFRIED, NICHOLAS THOMAS, SHULMAN, JOSHUA M · 2016 to 2020
$3.2M
Biogenesis of macromolecular machines for post-transcriptional regulation of translationR35GM138123 · NIGMS · EMORY UNIVERSITY · PI Homa Ghalei · 2020 to 2026
$3.0M
NIA NIH HHS R01 AG053960NIA NIH HHS R01 AG061800NIA NIH HHS RF1 AG062181NIA NIH HHS U01 AG046161NIA NIH HHS U01 AG061357NIGMS NIH HHS R35 GM138123NIGMS NIH HHS T32 GM008367NINDS NIH HHS T32 NS007480
6 · The paper itself

Abstract

Posttranslational modifications (PTMs) such as phosphorylation of RNA-binding proteins (RBPs) regulate several critical steps in RNA metabolism, including spliceosome assembly, alternative splicing, and mRNA export. Notably, serine-/arginine- (SR)-rich RBPs are densely phosphorylated compared with the remainder of the proteome. Previously, we showed that dephosphorylation of the splicing factor SRSF2 regulated increased interactions with similar arginine-rich RBPs U1-70K and LUC7L3. However, the large-scale functional and structural impact of these modifications on RBPs remains unclear. In this work, we dephosphorylated nuclear extracts using phosphatase in vitro and analyzed equal amounts of detergent-soluble and -insoluble fractions by mass-spectrometry-based proteomics. Correlation network analysis resolved 27 distinct modules of differentially soluble nucleoplasm proteins. We found classes of arginine-rich RBPs that decrease in solubility following dephosphorylation and enrich the insoluble pelleted fraction, including the SR protein family and the SR-like LUC7L RBP family. Importantly, increased insolubility was not observed across broad classes of RBPs. We determined that phosphorylation regulated SRSF2 structure, as dephosphorylated SRSF2 formed high-molecular-weight oligomeric species in vitro. Reciprocally, phosphorylation of SRSF2 by serine/arginine protein kinase 2 (SRPK2) in vitro decreased high-molecular-weight SRSF2 species formation. Furthermore, upon pharmacological inhibition of SRPKs in mammalian cells, we observed SRSF2 cytoplasmic mislocalization and increased formation of cytoplasmic granules as well as cytoplasmic tubular structures that associated with microtubules by immunocytochemical staining. Collectively, these findings demonstrate that phosphorylation may be a critical modification that prevents arginine-rich RBP insolubility and oligomerization.

Indexed as

Protein MultimerizationHEK293 CellsHumansNuclear ProteinsPhosphorylationProtein Serine-Threonine KinasesProtein StabilityRibonucleoprotein, U1 Small NuclearSerine-Arginine Splicing FactorsLUC7L3 protein, humanNuclear ProteinsProtein Serine-Threonine KinasesRibonucleoprotein, U1 Small NuclearSerine-Arginine Splicing FactorsSNRNP70 protein, humanSRPK2 protein, humanSRSF2 protein, humanmass spectrometryphosphorylationposttranslational modifications (PTMs)protein interactionsRNA-binding proteinsSC35SRSF2

Identifiers

PMID34673031
PMCPMC8569591
OpenAlexW3207487206

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.